Hay JW - Search Results

1

A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma.

Lam J, Hay JW, Salcedo J, Kenyon NJ. Lam J, et al. Among authors: hay jw. J Asthma. 2019 Aug;56(8):872-881. doi: 10.1080/02770903.2018.1500584. Epub 2018 Aug 29. J Asthma. 2019. PMID: 30003833

2

Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function.

Salcedo J, Hay JW, Lam J. Salcedo J, et al. Among authors: hay jw. Int J Cardiol. 2019 May 1;282:53-58. doi: 10.1016/j.ijcard.2018.11.087. Epub 2018 Nov 19. Int J Cardiol. 2019. PMID: 30518479

3

Reconstruction After Salvage Total Laryngectomy: A Cost-effectiveness Analysis.

Acevedo JR, Yu JC, Cameron B, Nurimba M, Hay JW, Kokot NC. Acevedo JR, et al. Among authors: hay jw. Otolaryngol Head Neck Surg. 2021 Jan;164(1):139-145. doi: 10.1177/0194599820936264. Epub 2020 Jul 14. Otolaryngol Head Neck Surg. 2021. PMID: 32660337

4

Behavioral Economics Interventions to Improve Outpatient Antibiotic Prescribing for Acute Respiratory Infections: a Cost-Effectiveness Analysis.

Gong CL, Zangwill KM, Hay JW, Meeker D, Doctor JN. Gong CL, et al. Among authors: hay jw. J Gen Intern Med. 2019 Jun;34(6):846-854. doi: 10.1007/s11606-018-4467-x. Epub 2018 May 8. J Gen Intern Med. 2019. PMID: 29740788 Free PMC article.

5

Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States.

Cho SK, Hay JW, Barzi A. Cho SK, et al. Among authors: hay jw. Clin Colorectal Cancer. 2018 Dec;17(4):e751-e761. doi: 10.1016/j.clcc.2018.08.003. Epub 2018 Aug 24. Clin Colorectal Cancer. 2018. PMID: 30228027 Clinical Trial.

6

Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.

Aliyev ER, Hay JW, Hwang C. Aliyev ER, et al. Among authors: hay jw. Pharmacotherapy. 2019 Feb;39(2):118-128. doi: 10.1002/phar.2208. Epub 2019 Jan 20. Pharmacotherapy. 2019. PMID: 30565265

7

A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.

Drabo EF, Hay JW, Vardavas R, Wagner ZR, Sood N. Drabo EF, et al. Among authors: hay jw. Clin Infect Dis. 2016 Dec 1;63(11):1495-1504. doi: 10.1093/cid/ciw578. Epub 2016 Aug 23. Clin Infect Dis. 2016. PMID: 27558571

8

Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.

Villacorta R, Hay JW, Messali A. Villacorta R, et al. Among authors: hay jw. Pharmacoeconomics. 2013 Sep;31(9):823-39. doi: 10.1007/s40273-013-0078-x. Pharmacoeconomics. 2013. PMID: 23975739

9

First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective.

Hu X, Hay JW. Hu X, et al. Among authors: hay jw. Lung Cancer. 2018 Sep;123:166-171. doi: 10.1016/j.lungcan.2018.07.012. Epub 2018 Jul 11. Lung Cancer. 2018. PMID: 30089590

10

Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.

Mehta DA, Hay JW. Mehta DA, et al. Among authors: hay jw. Gynecol Oncol. 2014 Mar;132(3):677-83. doi: 10.1016/j.ygyno.2014.01.021. Epub 2014 Jan 23. Gynecol Oncol. 2014. PMID: 24463160

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

155 results

Search Page

Filters